COMMERCIAL EVIDENCE WORKBENCH
Every claim.
Backed by evidence.
Find the gaps between what a draft says
and what its sources actually support.
Claims in this draft
06Each traced to source evidenceNeed a closer look
03Flagged by explicit rule checksCurrent source
v13WINREVAIR · Oct 08 2026Reviewed on this device
00Human decisions, saved locallyClaim review 6
Evidence findings support human review.
EVIDENCE INSPECTOR
Look beyond the claim.
Eligibility qualifiers need review
The draft does not state adult population and WHO Group 1. Check the full context before broadening the referenced indication.
Source evidence3 passages retrieved
1 INDICATIONS AND USAGE
WINREVAIR™ is indicated for the treatment of adults with pulmonary arterial hypertension (PAH, Group 1 pulmonary hypertension) to improve exercise capacity and World Health Organization (WHO) functional class (FC), and reduce the risk of clinical worsening events including hospitalization for PAH, lung transplantation and death [see Clinical Studies (14.1) ] .
Retrieved by BM25 · not a support verdict
Neural evidence checkDeBERTa · INT8
Model suggests support Recorded AI run
Model probabilities, not calibrated confidence. Rules and human review remain separate. Compared with .
First run loads ~96 MB of model files. Cached on this browser.
Your review
Saved on this deviceA review record is not approval to publish.
Public US labeling. Fictional drafts. Human review required.